[go: up one dir, main page]

SI1827437T1 - Kombinacije terapevtskih sredstev za zdravljenje raka - Google Patents

Kombinacije terapevtskih sredstev za zdravljenje raka

Info

Publication number
SI1827437T1
SI1827437T1 SI200531442T SI200531442T SI1827437T1 SI 1827437 T1 SI1827437 T1 SI 1827437T1 SI 200531442 T SI200531442 T SI 200531442T SI 200531442 T SI200531442 T SI 200531442T SI 1827437 T1 SI1827437 T1 SI 1827437T1
Authority
SI
Slovenia
Prior art keywords
inhibitor
kinase inhibitor
combinations
therapeutic agents
treating cancer
Prior art date
Application number
SI200531442T
Other languages
English (en)
Inventor
Sara Zaknoen
Margaret Ma Woo
Richard William Versace
Claudio Pisano
Loredana Vesci
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36463409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1827437(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of SI1827437T1 publication Critical patent/SI1827437T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
SI200531442T 2004-12-15 2005-12-13 Kombinacije terapevtskih sredstev za zdravljenje raka SI1827437T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63643904P 2004-12-15 2004-12-15
PCT/US2005/044993 WO2006065780A2 (en) 2004-12-15 2005-12-13 Combinations of therapeutic agents for treating cancer
EP05853820A EP1827437B1 (en) 2004-12-15 2005-12-13 Combinations of therapeutic agents for treating cancer

Publications (1)

Publication Number Publication Date
SI1827437T1 true SI1827437T1 (sl) 2012-02-29

Family

ID=36463409

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531442T SI1827437T1 (sl) 2004-12-15 2005-12-13 Kombinacije terapevtskih sredstev za zdravljenje raka

Country Status (26)

Country Link
US (1) US8975248B2 (sl)
EP (1) EP1827437B1 (sl)
JP (1) JP5345323B2 (sl)
KR (1) KR101367516B1 (sl)
CN (1) CN101080227B (sl)
AT (1) ATE531371T1 (sl)
AU (1) AU2005316652B2 (sl)
BR (1) BRPI0515774A (sl)
CA (1) CA2589521C (sl)
CY (1) CY1112368T1 (sl)
DK (1) DK1827437T3 (sl)
ES (1) ES2374828T3 (sl)
HR (1) HRP20110960T1 (sl)
IL (1) IL183595A0 (sl)
MA (1) MA29096B1 (sl)
MX (1) MX2007007212A (sl)
NO (1) NO20073552L (sl)
NZ (1) NZ555370A (sl)
PL (1) PL1827437T3 (sl)
PT (1) PT1827437E (sl)
RU (1) RU2400232C2 (sl)
SI (1) SI1827437T1 (sl)
TN (1) TNSN07224A1 (sl)
TW (1) TW200628151A (sl)
WO (1) WO2006065780A2 (sl)
ZA (1) ZA200704701B (sl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122012021252B8 (pt) 2002-09-06 2021-05-25 Cerulean Pharma Inc polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência
SI1827437T1 (sl) 2004-12-15 2012-02-29 Sigma Tau Ind Farmaceuti Kombinacije terapevtskih sredstev za zdravljenje raka
US20080219977A1 (en) * 2005-07-27 2008-09-11 Isaiah Josh Fidler Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
WO2007057457A2 (en) * 2005-11-21 2007-05-24 Novartis Ag Neuroendocrine tumor treatment using mtor inhibitors
WO2007094026A1 (en) * 2006-02-17 2007-08-23 Paolo La Colla Prophylactic and/or therapeutic treatment of proliferative and conformational diseases
RU2447891C2 (ru) * 2006-04-05 2012-04-20 Новартис Аг Комбинации терапевтических средств, предназначенные для лечения рака
JP2009532497A (ja) * 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
MX2008012728A (es) * 2006-04-05 2008-10-14 Novartis Ag Combinaciones de agentes terapeuticos para el tratamiento de cancer.
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
EP2060565A1 (en) * 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CN101837129B (zh) * 2009-03-19 2012-12-12 鼎泓国际投资（香港）有限公司 含cMet抑制剂、HDAC抑制剂与EGFR酪氨酸激酶抑制剂的药物组合物及其应用
US20120114658A1 (en) * 2009-09-15 2012-05-10 John Ryan Treatment of cancer
EP2560647B1 (en) * 2010-04-19 2016-04-13 Niiki Pharma Inc. Combination therapy with a proteasome inhibitor and a gallium complex
LT2786753T (lt) 2010-11-12 2019-04-10 Pharma Mar S.A. Derinių terapija su antinavikiniu antibiotiku
CN102731516B (zh) * 2011-04-07 2014-07-02 宁波天衡药业股份有限公司 一类具有抗肿瘤活性的喜树碱衍生物
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
EP3125920B1 (en) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
RU2693463C2 (ru) * 2014-04-04 2019-07-03 Тайхо Фармасьютикал Ко., Лтд. Противоопухолевое средство, содержащее таксановое соединение и усилитель противоопухолевого эффекта
AU2015398613B2 (en) 2015-06-15 2021-08-12 Newsouth Innovations Pty Limited Pharmaceutical combinations of organo-arsenoxide compounds and mTOR inhibitors
CN107951888A (zh) * 2017-12-19 2018-04-24 天津科技大学 阿法替尼与10-羟基喜树碱的药物组合及其应用
CN109091480A (zh) * 2018-09-19 2018-12-28 天津科技大学 癌组合物10-羟基喜树碱和克唑替尼治疗肺癌及用途
CN113195000A (zh) * 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
CN111789903A (zh) * 2019-04-08 2020-10-20 石小和 治疗尿道癌的药物组合物及其制备方法
AU2020388196B2 (en) 2019-11-21 2025-08-14 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
CN120695174A (zh) * 2021-07-01 2025-09-26 江苏先声生物制药有限公司 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
WO2023165603A1 (en) * 2022-03-03 2023-09-07 Zai Lab (Shanghai) Co., Ltd. Dna-pk inhibitor and combination use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1369116A1 (en) 1994-11-11 2003-12-10 Debiopharm S.A. Oxalatoplatin and 5-fluorouracil for combination therapy of cancer
JPH08169825A (ja) * 1994-12-15 1996-07-02 Tanaka Kikinzoku Kogyo Kk 抗癌剤の併用投与方法及び併用可能な抗癌剤
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US20020103141A1 (en) 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
US7105492B2 (en) 1999-03-09 2006-09-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
SI1044977T1 (sl) * 1999-03-09 2002-08-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Derivati kamptotecina, ki imajo protitumorno delovanje
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US20050038048A1 (en) 2001-10-29 2005-02-17 Ball Howard Ashley Use of 7h-pyrrollo{2,3-d}pyrimidine derivatives in the treatment of solid tumor diseases
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
BR0312597A (pt) * 2002-07-11 2005-05-10 Combinatorx Inc Combinações de drogas para o tratamento de neoplasmas
WO2004103358A2 (en) * 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents
WO2005117980A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
SI1827437T1 (sl) 2004-12-15 2012-02-29 Sigma Tau Ind Farmaceuti Kombinacije terapevtskih sredstev za zdravljenje raka
JP4702322B2 (ja) 2006-12-14 2011-06-15 トヨタ自動車株式会社 内燃機関の制御装置

Also Published As

Publication number Publication date
KR20070091286A (ko) 2007-09-10
MA29096B1 (fr) 2007-12-03
EP1827437A2 (en) 2007-09-05
CA2589521C (en) 2014-04-01
KR101367516B1 (ko) 2014-02-27
BRPI0515774A (pt) 2008-08-05
RU2007126978A (ru) 2009-01-27
PL1827437T3 (pl) 2013-06-28
ATE531371T1 (de) 2011-11-15
US20100028338A1 (en) 2010-02-04
HRP20110960T1 (hr) 2012-01-31
TNSN07224A1 (en) 2008-11-21
CA2589521A1 (en) 2006-06-22
AU2005316652B2 (en) 2009-07-23
EP1827437B1 (en) 2011-11-02
ES2374828T3 (es) 2012-02-22
NO20073552L (no) 2007-09-12
JP5345323B2 (ja) 2013-11-20
WO2006065780A2 (en) 2006-06-22
RU2400232C2 (ru) 2010-09-27
CN101080227A (zh) 2007-11-28
IL183595A0 (en) 2007-10-31
US8975248B2 (en) 2015-03-10
AU2005316652A1 (en) 2006-06-22
CY1112368T1 (el) 2015-12-09
DK1827437T3 (da) 2012-02-13
TW200628151A (en) 2006-08-16
JP2008524225A (ja) 2008-07-10
CN101080227B (zh) 2011-08-31
PT1827437E (pt) 2012-01-12
MX2007007212A (es) 2007-11-07
NZ555370A (en) 2010-03-26
WO2006065780A3 (en) 2006-08-17
ZA200704701B (en) 2008-09-25

Similar Documents

Publication Publication Date Title
TNSN07224A1 (en) Combinations of therapeutic agents for treating cancer
NO20061777L (no) Kombinasjon av en VEGF-resptorinhibitor og er kjemopteraputisk middel
ES2654623T3 (es) Inhibidores bivalentes de proteínas IAP y métodos terapéuticos que los usan
Ferrario et al. Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model
MXPA05013642A (es) Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer.
RU2008152435A (ru) Композиции и способы регулирования развития сосудов
MXPA02011379A (es) Ensayo de deteccion de genes para mejorar la probabilidad de una respuesta efectiva a terapia de cancer con el antagonista erbb.
MXPA02011913A (es) Triazolopirimidinas sustituidas como agentes anticancer.
WO2004037341A3 (en) Method and device for treating concer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy
AU2002340168A1 (en) Treatment of prostate cancer by inhibitors of ncam2
BG108072A (en) The use of epothilone derivatives for the treatment of refractory tumors
EA200801309A1 (ru) ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ
AU2003244762A1 (en) Methods and compositions for intravesical therapy of bladder cancer
JP2014144979A (ja) 治療におけるアポトーシスを増加させるための有糸分裂の阻害剤
ATE381930T1 (de) Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor
RU99126204A (ru) Способ лечения рака легкого
AR063459A1 (es) Metodo para administrar un inhibidor de aurora en el tratamiento del cancer
RU2005110536A (ru) Способ лечения рака
TW200503798A (en) Arsenic-containing pharmaceutical composition for treatment of tumor/cancer in conjunction with radiation therapy
DK1687642T3 (da) Screeningsfremgangsmåder til kombinationer af biologiske forbindelser
EA202092513A1 (ru) Комбинированная терапия